Chongqing Pharscin Pharmaceutical Co Ltd (002907) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.000x

Based on the latest financial reports, Chongqing Pharscin Pharmaceutical Co Ltd (002907) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥833.94K ≈ $122.03K USD) by net assets (CN¥1.71 Billion ≈ $250.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Chongqing Pharscin Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Chongqing Pharscin Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Chongqing Pharscin Pharmaceutical Co Ltd (002907) total liabilities for a breakdown of total debt and financial obligations.

Chongqing Pharscin Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Chongqing Pharscin Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Ratos AB (publ) ST:RATO-B	0.042x
Tsakos Energy Navigation Ltd NYSE:TEN	0.046x
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	0.022x
Shinkong Synthetic Fiber Corp TW:1409	-0.061x
Omada Health, Inc. Common Stock NASDAQ:OMDA	0.047x
Sri Trang Agro-Industry Public Company Limited BK:STA	-0.008x
Ottogi KO:007310	0.057x
GuangDong Rifeng Electric Cable Co Ltd SHE:002953	0.025x

Annual Cash Flow Conversion Efficiency for Chongqing Pharscin Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Chongqing Pharscin Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Chongqing Pharscin Pharmaceutical Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.66 Billion ≈ $242.91 Million	CN¥161.77 Million ≈ $23.67 Million	0.097x	-28.12%
2023-12-31	CN¥1.62 Billion ≈ $236.75 Million	CN¥219.34 Million ≈ $32.10 Million	0.136x	+1573.59%
2022-12-31	CN¥1.61 Billion ≈ $235.65 Million	CN¥13.04 Million ≈ $1.91 Million	0.008x	-87.62%
2021-12-31	CN¥1.27 Billion ≈ $185.24 Million	CN¥82.85 Million ≈ $12.12 Million	0.065x	-31.94%
2020-12-31	CN¥1.18 Billion ≈ $172.94 Million	CN¥113.64 Million ≈ $16.63 Million	0.096x	+56.20%
2019-12-31	CN¥1.07 Billion ≈ $156.69 Million	CN¥65.92 Million ≈ $9.65 Million	0.062x	+60.48%
2018-12-31	CN¥828.91 Million ≈ $121.30 Million	CN¥31.80 Million ≈ $4.65 Million	0.038x	-66.05%
2017-12-31	CN¥719.95 Million ≈ $105.35 Million	CN¥81.34 Million ≈ $11.90 Million	0.113x	-9.70%
2016-12-31	CN¥461.42 Million ≈ $67.52 Million	CN¥57.73 Million ≈ $8.45 Million	0.125x	-30.78%
2015-12-31	CN¥365.71 Million ≈ $53.51 Million	CN¥66.10 Million ≈ $9.67 Million	0.181x	+167.95%
2014-12-31	CN¥299.77 Million ≈ $43.87 Million	CN¥20.22 Million ≈ $2.96 Million	0.067x	-65.66%
2013-12-31	CN¥240.97 Million ≈ $35.26 Million	CN¥47.34 Million ≈ $6.93 Million	0.196x	--

About Chongqing Pharscin Pharmaceutical Co Ltd

SHE:002907 China Drug Manufacturers - Specialty & Generic

Market Cap

$852.45 Million

CN¥5.83 Billion CNY

Market Cap Rank

#9841 Global

#2783 in China

Share Price

CN¥13.95

Change (1 day)

+0.14%

52-Week Range

CN¥12.88 - CN¥21.87

All Time High

CN¥42.89